University of Texas's MD Anderson Cancer Center: Immunotherapy Before Surgery Associated With Improved Survival for Soft-Tissue Sarcoma
June 06, 2022
June 06, 2022
HOUSTON, Texas, June 6 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 4, 2022:
* * *
Phase II study supports further evaluation of neoadjuvant immune checkpoint blockade in early-stage undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
* * *
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcome . . .
* * *
Phase II study supports further evaluation of neoadjuvant immune checkpoint blockade in early-stage undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
* * *
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcome . . .